DOCSLIB.ORG

Atc Index 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atc Index 2010 ATC INDEX 2010 This is a version of the World Health Organization (WHO) ATC index and, as such, contains some substances for which data are not available in the two tables. This ATC index is sorted alphabetically according to generic/substance International Nonproprietary Name (INN). There may be some variance in the spelling of the generic name. 287 A L 04 A B 04 Adalimumab A 03 A B 16 (2-benzhydryloxyethyl) D 10 A D 03 Adapalene diethyl-methylammonium iodide D 10 A D 53 Adapalene, combinations D 01 A E 06 2-(4-chlorphenoxy)- ethanol J 05 A F 08 Adefovir dipivoxil V 03 A B 27 4-dimethylaminophenol A 16 A A 02 Ademetionine J 05 A F 06 Abacavir C 01 E B 10 Adenosine L 02 B X 01 Abarelix N 05 B A 07 Adinazolam L 04 A A 24 Abatacept V 08 A C 04 Adipiodone B 01 A C 13 Abciximab N 06 B X 17 Adrafinil L 04 A A 22 Abetimus A 01 A D 06 Adrenalone B 02 B C 01 Absorbable gelatin sponge B 02 B C 05 Adrenalone C 01 E B 13 Acadesine L 04 A B 03 Afelimomab N 07 B B 03 Acamprosate A 16 A B 03 Agalsidase alfa A 10 B F 01 Acarbose A 16 A B 04 Agalsidase beta C 07 A B 04 Acebutolol A 11 A H Agents for atopic dermatitis, excluding C 07 B B 04 Acebutolol and thiazides corticosteroids S 01 E B 08 Aceclidine N 06 A X 22 Agomelatine S 01 E B 58 Aceclidine, combinations C 01 B A 05 Ajmaline M 01 A B 16 Aceclofenac B 05 X B 02 Alanyl glutamine M 02 A A 25 Aceclofenac N 06 A B 07 Alaproclate R 03 D A 09 Acefylline piperazine P 02 C A 03 Albendazole M 01 A B 11 Acemetacin B 05 A A 01 Albumin B 01 A A 07 Acenocoumarol A 07 X A 01 Albumin tannate N 05 A A 04 Acepromazine A 07 X A 51 Albumin tannate, combinations A 07 A X 02 Acetarsol M 01 A B 06 Alclofenac G 01 A B 01 Acetarsol D 07 A B 10 Alclometasone P 01 C D 02 Acetarsol S 01 B A 10 Alclometasone S 01 E C 01 Acetazolamide M 03 A A 01 Alcuronium G 01 A D 02 Acetic Acid L 03 A C 01 Aldesleukin S 02 A A 10 Acetic Acid J 04 B A 03 Aldesulfone sodium A 10 B B 31 Acetohexamide H 02 A A 01 Aldosterone G 04 B X 03 Acetohydroxamic acid L 04 A A 15 Alefacept N 05 A B 07 Acetophenazine L 01 X C 04 Alemtuzumab A 02 B X 09 Acetoxolone M 05 B A 04 Alendronic acid V 08 A A 07 Acetrizoic acid M 05 B B 03 Alendronic acid and colecalciferol N 06 B X 12 Acetylcarnitine B 02 A B 02 Alfal antitrypsin S 01 E B 09 Acetylcholine A 11 C C 03 Alfacalcidol R 05 C B 01 Acetylcysteine N 01 A X 05 Alfaxalone S 01 X A 08 Acetylcysteine N 01 A H 02 Alfentanil V 03 A B 23 Acetylcysteine G 04 C A 51 Alfuzosin and finasteride C 01 A A 01 Acetyldigitoxin G 04 C A 01 Alfuzosin C 01 A A 02 Acetyldigoxin A 02 A B 02 Algeldrate C 01 A A 52 Acetyldigoxin, combinations A 02 B X 13 Alginic acid R 05 D A 12 Acetyldihydrocodeine A 16 A B 01 Alglucerase N 05 C C 03 Acetylglycinamide chloral hydrate A 16 A B 07 Alglucosidase alfa N 07 C A 04 Acetylleucine R 06 A D 01 Alimemazine A 01 A D 05 Acetylsalicylic acid C 10 A X 10 Alipogene tiparvovec B 01 A C 06 Acetylsalicylic acid C 09 X A 02 Aliskiren N 02 B A 01 Acetylsalicylic acid C 09 X A 52 Aliskiren and hydrochlorothiazide M 01 B A 03 Acetylsalicylic acid and corticosteroids D 11 A X 19 Alitretinoin N 02 B A 51 Acetylsalicylic acid, comb. excl. psycholeptics L 01 X X 22 Alitretinoin N 02 B A 71 Acetylsalicylic acid, comb. with psycholeptics A 03 F A 05 Alizapride D 06 B B 03 Aciclovir N 05 C A 21 Allobarbital J 05 A B 01 Aciclovir M 04 A A 01 Allopurinol S 01 A D 03 Aciclovir M 04 A A 51 Allopurinol, combinations D 06 B B 53 Aciclovir, combinations G 03 D C 01 Allylestrenol C 10 A D 06 Acipimox A 02 A D 03 Almagate D 05 B B 02 Acitretin A 02 A D 03 Almasilate L 01 D B 04 Aclarubicin M 01 A E 16 Alminoprofen R 02 A A 13 Acriflavinium chloride R 07 A B 07 Almitrine R 06 A X 18 Acrivastine N 02 C C 05 Almotriptan 288 A 10 B H 04 Alogliptin N 02 B B 73 Aminophenazone, combinations with A 02 A B 06 Aloglutamol psycholeptics A 03 A E 01 Alosetron R 03 D A 05 Aminophylline B 01 A C 15 Aloxiprin R 03 D B 05 Aminophylline and adrenergics N 02 B A 02 Aloxiprin R 03 D A 55 Aminophylline, combinations N 05 B A 12 Alprazolam J 04 A A 01 Aminosalicylic acid C 07 A A 01 Alprenolol C 01 B D 01 Amiodarone C 01 E A 01 Alprostadil N 05 A L 05 Amisulpride G 04 B E 01 Alprostadil N 06 A A 09 Amitriptyline V 04 C H 04 Alsactide N 06 C A 01 Amitriptyline and psycholeptics B 01 A D 02 Alteplase A 01 A D 07 Amlexanox S 01 X A 13 Alteplase R 03 D X 01 Amlexanox R 05 C A 05 Althea root C 08 C A 01 Amlodipine C 03 E A 04 Altizide and potassium-sparing agents B 05 X A 04 Ammonium chloride L 01 X X 03 Altretamine G 04 B A 01 Ammonium chloride S 01 X A 07 Alum N 05 C A 02 Amobarbital A 02 A B 05 Aluminium acetoacetate P 01 B A 06 Amodiaquine S 02 A A 04 Aluminium acetotartrate D 01 A E 16 Amorolfine D 10 A X 01 Aluminium chloride N 06 A A 17 Amoxapine D 09 A A 08 Aluminium Chlorohydrate J 01 C A 04 Amoxycillin M 05 B X 02 Aluminium Chlorohydrate J 01 C R 02 Amoxycillin and enzyme inhibitor C 10 A B 03 Aluminium clofibrate A 01 A B 04 Amphotericin B A 02 A B 07 Aluminium glycinate A 07 A A 07 Amphotericin B A 02 A B 01 Aluminium hydroxide G 01 A A 03 Amphotericin B C 10 A D 04 Aluminium nicotinate J 02 A A 01 Amphotericin B D 10 A X 04 Aluminium oxide J 01 C A 01 Ampicillin A 02 A B 03 Aluminium phosphate S 01 A A 19 Ampicillin C 05 A X 01 Aluminium preparations J 01 C R 01 Ampicillin and enzyme inhibitor A 03 A X 08 Alverine J 01 C A 51 Ampicillin, combinations A 03 A X 58 Alverine, combinations J 05 A E 05 Amprenavir A 06 A H 02 Alvimopan C 01 C E 01 Amrinone N 04 B B 01 Amantadine L 01 X X 01 Amsacrine R 02 A A 01 Ambazone V 03 A B 22 Amyl nitrite N 07 A A 30 Ambenonium L 01 X X 35 Anagrelide C 02 K X 02 Ambriesentan L 04 A C 03 Anakinra R 05 C B 06 Ambroxol S 02 D A Analgesics and anesthetics A 03 C A 07 Ambutonium and psychleptics L 02 B G 03 Anastrozole D 07 A C 11 Amcinonide L 03 A A 12 Ancestim A 08 A A 03 Amfepramone B 01 A D 09 Ancrod N 06 B A 01 Amfetamine A 14 A A 01 Androstanolone N 07 X X 05 Amifampridine G 03 B B 02 Androstanolone V 03 A F 05 Amifostine S 01 X A 16 Anecortave D 06 A X 12 Amikacin A 16 A X 02 Anethole trithione J 01 G B 06 Amikacin C 09 D B Angiotensin II anatagonists and calcium S 01 A A 21 Amikacin channel blockers C 03 D B 01 Amiloride C 09 D X Angiotensin II anatagonists, other combinations N 06 A A 19 Amineptine C 01 C X 06 Angiotensinamide B 05 B A 01 Amino acids J 02 A X 06 Anidulafungin N 03 A B 03 Amino (diphenylhydantoin) valeric acid N 01 A H 05 Anileridine D 08 A A 02 Aminoacridine V 01 A A 11 Animals D 02 B A 01 Aminobenzoic acid N 06 B X 11 Aniracetam N 03 A G 03 Aminobutyric acid B 01 A D 03 Anistreplase B 02 A A 01 Aminocaproic acid A 02 A X Antacids, other combinations L 02 B G 01 Aminogluthetimide R 01 A C 04 Antazoline V 04 C H 30 Aminohippuric acid R 06 A X 05 Antazoline L 01 X D 04 Aminolevulinic acid J 07 A C 01 Anthrax antigen B 02 A A 03 Aminomethylbenzoic acid D 06 A X Antibiotics for topical use, other N 02 B B 03 Aminophenazone S 01 A A 20 Antibiotics in combination with other drugs N 02 B B 53 Aminophenazone, combinations excl.
Load more

Recommended publications
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Lifestyle Drugs” for Men and Women
    Development of “Lifestyle Drugs” for Men and Women Armin Schultz CRS - Clinical Research Services Mannheim GmbH AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Smart drugs, Quality-of-life drugs, Vanity drugs etc. Lifestyle? Lifestyle-Drugs? Active development? Discovery by chance? AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle A lifestyle is a characteristic bundle of behaviors that makes sense to both others and oneself in a given time and place, including social relations, consumption, entertainment, and dress. The behaviors and practices within lifestyles are a mixture of habits, conventional ways of doing things, and reasoned actions „Ein Lebensstil ist [...] der regelmäßig wiederkehrende Gesamtzusammenhang der Verhaltensweisen, Interaktionen, Meinungen, Wissensbestände und bewertenden Einstellungen eines Menschen“ (Hradil 2005: 46) Different definitions in social sciences, philosophy, psychology or medicine AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle Many “subdivisions” LOHAS: “Lifestyles of Health and Sustainability“ LOVOS: “Lifestyles of Voluntary Simplicity“ SLOHAS: “Slow Lifestyles of Happiness and Sustainability” PARKOS: “Partizipative Konsumenten“ ……. ……. ……. AGAH Annual Meeting 2012, Leipzig, March 01 - 02 Lifestyle drugs Lifestyle drug is an imprecise term commonly applied to medications which treat non-life threatening and non-painful conditions such as baldness, impotence, wrinkles, or acne, without any medical relevance at all or only minor medical relevance relative to others. Desire for increase of personal well-being and quality of life It is sometimes intended as a pejorative, bearing the implication that the scarce medical research resources allocated to develop such drugs were spent frivolously when they could have been better spent researching cures for more serious medical conditions.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Modafinil and Modafinil Analogues: Free Radical Mechanism of the Eugeroic and Cognitive Enhancment Effect Clifford Fong
    Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford Fong To cite this version: Clifford Fong. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect. [Research Report] Eigenenergy. 2018. hal-01933737 HAL Id: hal-01933737 https://hal.archives-ouvertes.fr/hal-01933737 Submitted on 24 Nov 2018 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Modafinil and modafinil analogues: free radical mechanism of the eugeroic and cognitive enhancment effect Clifford W. Fong Eigenenergy, Adelaide, South Australia. Keywords: Modafinil, modafinil-like analogues, eugeroic effect, cognitive enhancement, free radicals, quantum mechanics Abbreviations Dopamine DA, dopamine transporter DAT, Dissociative electron transfer or attachment DET, Linear free energy relationship LFER, free energy of water desolvation ΔG desolv,CDS , lipophilicity free energy ΔG lipo,CDS, cavity dispersion solvent structure of the first solvation shell CDS, highest occupied molecular orbital HOMO, lowest unoccupied molecular orbital LUMO, multiple correlation coefficient R 2, the F test of significance, standards errors for the estimate (SEE) and standard errors of the variables SE(ΔG desolCDS ), SE(ΔG lipoCDS ), SE(Dipole Moment), SE (Molecular Volume), transition state TS, reactive oxygen species ROS.
    [Show full text]
  • Survey and Risk Assessment of Chemical Substances in Deodorants
    Survey and risk assessment of chemical substances in deodorants Suresh C. Rastogi & Gitte Hellerup Jensen National Environmental Research Institute Jeanne Duus Johansen National Allergy Research Centre Survey of Chemical Substances in Consumer Products, No. 86 2007 The Danish Environmental Protection Agency will, when opportunity offers, publish reports and contributions relating to environmental research and development projects financed via the Danish EPA. Please note that publication does not signify that the contents of the reports necessarily reflect the views of the Danish EPA. The reports are, however, published because the Danish EPA finds that the studies represent a valuable contribution to the debate on environmental policy in Denmark. Contents SAMMENFATNING 5 SUMMARY 7 1 INTRODUCTION 11 2 MARKET SURVEY AND PRODUCT SAMPLING 13 2.1 MARKET SURVEY 13 2.2 LEGISLATION 15 2.3 SAMPLING OF PRODUCTS AND CONTROL OF LABELLING 15 2.4 SELECTION OF PRODUCTS FOR ANALYSIS 18 3 ANALYSIS 19 3.1 MATERIALS 19 3.2 ANALYSIS 19 3.2.1 Sample preparation 19 3.2.2 Analysis of fragrance substances 19 3.2.3 Analysis of triclosan 20 4 RESULTS 21 5 RISK ASSESSMENT 27 5.1 DEODORANTS AND CONTACT ALLERGY 27 5.2 RISK ASSESSMENT – IN GENERAL 27 5.3 THE SELECTED FRAGRANCE SUBSTANCES 28 5.3.1 HYDOXYISOHEXYL 3-CYCLOHEXENE CARBOXALDEHYDE (HICC) 28 5.3.2 HYDROXYCITRONELLAL 32 5.3.3 ISOEUGENOL 33 5.3.4 CINNAMAL/CINNAMYL ALCOHOL 34 5.4 FARNESOL 35 5.5 COMMENTS CONCERNING OTHER FRAGRANCE SUBSTANCES 35 5.6 ALLERGEN LOAD OF FRAGRANCE SUBSTANCES 36 5.7 TRICLOSAN 36 6 DISCUSSION 38 7 REFERENCES 43 ANNEX 1 49 3 4 Sammenfatning Deodoranter anvendes dagligt af store dele af befolkningen og kan indeholde ingredienser, som visse duftstoffer og konserveringsmidler, der er hyppige år- sager til hudallergi.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20050181041A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0181041 A1 Goldman (43) Pub. Date: Aug. 18, 2005 (54) METHOD OF PREPARATION OF MIXED Related US. Application Data PHASE CO-CRYSTALS WITH ACTIVE AGENTS (60) Provisional application No. 60/528,232, ?led on Dec. 9, 2003. Provisional application No. 60/559,862, ?led (75) Inventor: David Goldman, Portland, CT (US) on Apr. 6, 2004. Correspondence Address: Publication Classi?cation LEYDIG VOIT & MAYER, LTD (51) Int. Cl.7 ....................... .. A61K 31/56; A61K 38/00; TWO PRUDENTIAL PLAZA, SUITE 4900 A61K 9/64 180 NORTH STETSON AVENUE (52) US. Cl. ............................ .. 424/456; 514/179; 514/2; CHICAGO, IL 60601-6780 (US) 514/221 (73) Assignee: MedCrystalForms, LLC, Hunt Valley, (57) ABSTRACT MD This invention pertains to a method of preparing mixed phase co-crystals of active agents With one or more materials (21) Appl. No.: 11/008,034 that alloWs the modi?cation of the active agent to a neW physical/crystal form With unique properties useful for the delivery of the active agent, as Well as compositions com (22) Filed: Dec. 9, 2004 prising the mixed phase co-crystals. Patent Application Publication Aug. 18, 2005 Sheet 1 0f 8 US 2005/0181041 A1 FIG. 1a 214.70°C z.m."m.n... 206.98°C n..0ao 142 OJ/g as:20m=3: -0.8 -1.0 40 90 1:10 2110 Temperture (°C) FIG. 1b 0.01 as:22“.Km: 217 095 24221.4 39Jmum/Q -0.8 35 155 255 255 Temperture (°C) Patent Application Publication Aug.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann Et Al
    US 2014O127257A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0127257 A1 Schiemann et al. (43) Pub. Date: May 8, 2014 (54) DERMATOLOGICALLY EFFECTIVE YEAST Publication Classification EXTRACT (51) Int. Cl. (75) Inventors: Yvonne Schiemann, Essen (DE); Mike A61E36/064 (2006.01) Farwick, Essen (DE); Thomas Haas, CI2P I/02 (2006.01) Muenster (DE); Mirja Wessel, Bochum A61E36/06 (2006.01) (DE) (52) U.S. Cl. CPC ............... A61K 36/064 (2013.01); A61K 36/06 (73) Assignee: EVONIK DEGUSSA GMBH, Essen (2013.01); CI2P I/02 (2013.01) (DE) USPC ...................................... 424/195.16; 435/171 (21) Appl. No.: 14/128,244 (22) PCT Fled: Jun. 14, 2012 (57) ABSTRACT (86) PCT NO.: PCT/EP2012/061263 The invention relates to a method for producing a dermato S371 (c)(1), logically active yeast extract, comprising the following steps: (2), (4) Date: Dec. 20, 2013 providing a preculture of the yeast cells, culturing the cells for (30) Foreign Application Priority Data at least fifteen minutes at a pH of 1.8-4, harvesting the cells and lysing the cells, and a yeast extract produced thereby and Jun. 29, 2011 (EP) .................................. 11171953.0 products comprising said yeast extract. Patent Application Publication May 8, 2014 Sheet 1 of 3 US 2014/O127257 A1 -0-Yarrowia------------ lipolytica -- Pichia CBS 1991 - A - Saccharomyces Cerevisiae Fig. 1 US 2014/O127257 A1 May 8, 2014 DERMATOLOGICALLY EFFECTIVE YEAST skin. Against the background of consumers’ uncertainty with EXTRACT respect to genetic engineering techniques, there is a particular demand for corresponding agents that can be regarded, 0001.
    [Show full text]
  • Page 1 Note: Within Nine Months from the Publication of the Mention
    Europäisches Patentamt (19) European Patent Office & Office européen des brevets (11) EP 1 411 992 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 49/04 (2006.01) A61K 49/18 (2006.01) 13.12.2006 Bulletin 2006/50 (86) International application number: (21) Application number: 02758379.8 PCT/EP2002/008183 (22) Date of filing: 23.07.2002 (87) International publication number: WO 2003/013616 (20.02.2003 Gazette 2003/08) (54) IONIC AND NON-IONIC RADIOGRAPHIC CONTRAST AGENTS FOR USE IN COMBINED X-RAY AND NUCLEAR MAGNETIC RESONANCE DIAGNOSTICS IONISCHES UND NICHT-IONISCHES RADIOGRAPHISCHES KONTRASTMITTEL ZUR VERWENDUNG IN DER KOMBINIERTEN ROENTGEN- UND KERNSPINTOMOGRAPHIEDIAGNOSTIK SUBSTANCES IONIQUES ET NON-IONIQUES DE CONTRASTE RADIOGRAPHIQUE UTILISEES POUR ETABLIR DES DIAGNOSTICS FAISANT APPEL AUX RAYONS X ET A L’IMAGERIE PAR RESONANCE MAGNETIQUE (84) Designated Contracting States: (74) Representative: Minoja, Fabrizio AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Bianchetti Bracco Minoja S.r.l. IE IT LI LU MC NL PT SE SK TR Via Plinio, 63 20129 Milano (IT) (30) Priority: 03.08.2001 IT MI20011706 (56) References cited: (43) Date of publication of application: EP-A- 0 759 785 WO-A-00/75141 28.04.2004 Bulletin 2004/18 US-A- 5 648 536 (73) Proprietor: BRACCO IMAGING S.p.A. • K HERGAN, W. DORINGER, M. LÄNGLE W.OSER: 20134 Milano (IT) "Effects of iodinated contrast agents in MR imaging" EUROPEAN JOURNAL OF (72) Inventors: RADIOLOGY, vol. 21, 1995, pages 11-17, • AIME, Silvio XP002227102 20134 Milano (IT) • K.M.
    [Show full text]
  • Chemistry, Spectroscopic Characteristics and Biological Activity of Natural Occurring Cardiac Glycosides
    IOSR Journal of Biotechnology and Biochemistry (IOSR-JBB) ISSN: 2455-264X, Volume 2, Issue 6 Part: II (Sep. – Oct. 2016), PP 20-35 www.iosrjournals.org Chemistry, spectroscopic characteristics and biological activity of natural occurring cardiac glycosides Marzough Aziz DagerAlbalawi1* 1 Department of Chemistry, University college- Alwajh, University of Tabuk, Saudi Arabia Abstract:Cardiac glycosides are organic compounds containing two types namely Cardenolide and Bufadienolide. Cardiac glycosides are found in a diverse group of plants including Digitalis purpurea and Digitalis lanata (foxgloves), Nerium oleander (oleander),Thevetiaperuviana (yellow oleander), Convallariamajalis (lily of the valley), Urgineamaritima and Urgineaindica (squill), Strophanthusgratus (ouabain),Apocynumcannabinum (dogbane), and Cheiranthuscheiri (wallflower). In addition, the venom gland of cane toad (Bufomarinus) contains large quantities of a purported aphrodisiac substance that has resulted in cardiac glycoside poisoning.Therapeutic use of herbal cardiac glycosides continues to be a source of toxicity today. Recently, D.lanata was mistakenly substituted for plantain in herbal products marketed to cleanse the bowel; human toxicity resulted. Cardiac glycosides have been also found in Asian herbal products and have been a source of human toxicity.The most important use of Cardiac glycosides is its affects in treatment of cardiac failure and anticancer agent for several types of cancer. The therapeutic benefits of digitalis were first described by William Withering in 1785. Initially, digitalis was used to treat dropsy, which is an old term for edema. Subsequent investigations found that digitalis was most useful for edema that was caused by a weakened heart. Digitalis compounds have historically been used in the treatment of chronic heart failure owing to their cardiotonic effect.
    [Show full text]
  • Prescription and Consumption of Solid Oral Drugs Dispensed As Unitary Doses in a Third Level Hospital
    Saudi Pharmaceutical Journal (2015) xxx, xxx–xxx King Saud University Saudi Pharmaceutical Journal www.ksu.edu.sa www.sciencedirect.com ORIGINAL ARTICLE Prescription and consumption of solid oral drugs dispensed as unitary doses in a third level hospital David Caldero´n-Guzma´n a, Hugo Jua´rez-Olguı´n b,c,*, Ernestina Herna´ndez-Garcı´a b, Alejandro Medina-Andrade b,c, Belen Juarez Tapia a a Laboratorio de Neuroquı´mica, Instituto Nacional de Pediatrı´a (INP), Mexico b Laboratorio de Farmacologı´a, INP, Mexico c Departamento de Farmacologı´a, Facultad de Medicina, Universidad Nacional Auto´noma de Me´xico, Mexico Received 17 February 2015; accepted 13 March 2015 KEYWORDS Abstract Background: The knowledge about the pattern of prescription and consumption of solid Drug prescriptions; oral drugs dispensed as unitary doses (UD) in Mexico is sparing. Purpose: The aim of this study was Hospital pharmacy; to describe the pattern of prescription and consumption of solid oral drugs dispensed as unitary Pharmacoepidemiology; doses (UD) in a third level private hospital of Mexico. A retrospective study of a 60-month period Unitary doses (from 2007 to 2011) was carried out to know the pattern of drugs dispensed as UD in a third level hospital. Results: Among the principal drugs consumed were analgesic, antihypertensive, antibiotic, anti-inflammatory, antiepileptic, and diuretics. The dispensation of drugs per year was as follows: 181 drugs with 85,167 UD in 2007; 199 with 90,519 UD in 2008; 193 with 101,479 UD in 2009; 195 with 100,798 UD in 2010; and 198 with 103,913 UD in 2011.
    [Show full text]